Chinese expert consensus of albumin-bound paclitaxel in the treatment of breast cancer.
10.3760/cma.j.cn112152-20230103-00006
- Collective Name:Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association;;International Medical Exchange Society, Chinese Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
Albumin-bound paclitaxel;
Breast neoplasms;
Clinical diagnosis and treatment;
Consensus
- MeSH:
Female;
Humans;
Albumin-Bound Paclitaxel/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Breast Neoplasms/drug therapy*;
Consensus;
East Asian People;
Quality of Life
- From:
Chinese Journal of Oncology
2023;45(3):203-211
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor of women, which seriously threatens women's health. Albumin-bound paclitaxel is the basic chemotherapy drug for breast cancer treatment. We can promote reasonable clinical medication and improve patients' quality of life by standardizing chemotherapy plans, rationally optimizing treatment strategy and managing adverse reactions of albumin-bound paclitaxel. In order to standardize the clinical application of albumin-bound paclitaxel in breast cancer, Chinese Medical Doctor Association Oncologist Branch Breast Cancer Group and International Medical Exchange Branch of China Anti-Cancer Association consulted guidelines and the latest evidence-based evidences and formulated Chinese expert consensus of albumin-bound paclitaxel in the treatment of breast cancer to provide reference for clinical diagnosis and treatment of breast cancer. The consensus mainly introduces the clinical application strategies and evidence-based evidences of albumin-bound paclitaxel in advanced therapy, neoadjuvant therapy and adjuvant therapy of breast cancer. Among them, the regimens containing albumin-bound paclitaxel are the better recommended regimens for preoperative neoadjuvant and advanced rescue therapy of breast cancer. However, there is little evidence in adjuvant therapy, so it is recommended to use albumin-bound paclitaxel cautiously. We also invited breast cancer clinical experts to vote on some controversial issues, including but not limited to the usage and dosage of albumin-bound paclitaxel, combined medication and management of peripheral neuropathy, and formed consensus recommendations for the reference of breast cancer clinical workers.
